FN Media Group Presents Oilprice.com Market Commentary
London – October 18, 2021 – A massive disruption now appears imminent in one of the world’s largest – and most important – industries. In much the same way that Amazon disrupted the retail business – and how PayPal disrupted the payments industry – one under-the-radar health technology company now seeks to transform the $11.85 trillion global health industry. Mentioned in today’s commentary includes: Sage Therapeutics, Inc. (NASDAQ: SAGE), Cassava Sciences, Inc. (NASDAQ: SAVA), Neuronetics, Inc. (NASDAQ: STIM), COMPASS Pathways plc (NASDAQ: CMPS), Acadia Healthcare Company, Inc. (NASDAQ: ACHC).
By moving healthcare away from brick and mortar, traditional medicine into an AI-driven tool that offers unprecedented speed, efficiency, and accuracy…Treatment.com (TRUE; TREIF) appears ready to change the face of medicine in a profound way.
Investors still have a brief window of opportunity to get in on this transformational investment opportunity while it still flies beneath Wall Street’s radar. But as you’ll soon discover, this company’s technology is so powerful that it could become a valuable addition to hundreds of millions of households worldwide.
Healthcare Is Going Digital
Whether most patients, providers, or large healthcare companies realize it or not, the healthcare industry is already in the early stages of significant change. That’s because patients now desire access to more information – and better information – in the blink of an eye.
In a recent survey of U.S. health consumers, 71% reported facing major frustrations through their experience with healthcare providers. Concerns ranged from difficulties scheduling appointments to impersonal visits. This means that the days of scheduling an appointment and spending hours in a doctor’s waiting room just to discuss a minor health issue could soon be long gone.
One billion people turn to Google each day to inquire about their health concerns. Wellness Apps were downloaded 1.2 billion times in 2020. And telemedicine grew 46% from 2019 to 2020. And the Covid-19 pandemic only accelerated this change, as millions of patients adapted to telehealth and online options for healthcare faster than they had imagined they ever would.
Treatment.com (TRUE; TREIF) is a disruptive, forward-thinking healthcare technology company that is using the power of Artificial Intelligence to help consumers improve their health through personalized recommendations and insights.
Their program proved to be so effective that the University of Minnesota Medical School actually licensed it for the purposes of testing its medical students. They spent over $10 million dollars – over five years – and worked with more than 100 doctors and 75 technical people to build the most personalized, intelligent healthcare AI on the planet.
In addition, the company’s technical team – responsible for building the AI – is led by some of Canada’s foremost experts on Artificial Intelligence and Machine Learning. Consumers are already turning to digital technology – in the form of Google searches or primitive health apps – to understand their general health and get answers to questions about their conditions. Now… with the launch of CARA – Treatment.com has hopes of permanently changing the access to healthcare for millions of patients.
Big Deals On The Horizon
Just recently – on September 15 – Treatment.com (TRUE; TREIF) took another significant step toward making CARA available to hundreds of millions of consumers. That’s the date that the company announced the consolidation of its advanced AI development capabilities with MentorMate, a leading healthcare software development firm based in the United States.
MentorMate is a global leader in mobile application development, with over 700 developers in the United State and the EU. Headquartered in Minneapolis near Treatment’s US operations, MentorMate specializes in advanced solutions for leading health care organizations. With over 19 years in business and over 1,400 completed projects, MentorMate has the experience and scale to support rapidly expanding products – which makes the company ideal to team up with Treatment.com.
An Undervalued, Under-the-Radar Opportunity
When compared with other companies in the space – many of which are still privately held – Treatment.com appears to offer investors an attractive, investment opportunity in a company that has the potential for significant growth in valuation.
This is a company that appears to be on the verge of bringing massive disruption to the $11.85 trillion healthcare industry…at the precise time when consumers are demanding just such a disruption. With a powerful, easy-to-use app – driven by its proprietary AI – Treatment.com is bringing consumers the type of improved healthcare access they’ve been searching for.
The Healthcare Industry Is Evolving
Sage Therapeutics (SAGE) is a biopharmaceutical company that develops medicines to treat rare diseases. The company was founded in 2003 by Dr. Jeffrey Cohen, who had previously discovered the first approved treatment for acute lymphoblastic leukemia (ALL). Sage Therapeutics has since gone on to create treatments for other cancers and genetic disorders, including Pompe disease, Sanfilippo syndrome type A, Fabry disease and Gaucher disease. These therapies have been approved in over 40 countries around the world and are changing lives every day.
Sage Therapuetics is a fantastic example of a company using its resources to tackle the growing mental health crisis in the United States and abroad. With a focus on exciting new ways to treat mental health disorders, the company released the only FDA-approved treatment for post-partum depression. It’s drug, Zulresso, soared through clinical trials with no issues, and is advertised to help mothers feel better in just 2.5 days.
Cassava Sciences (SAVA) is a company that aims to make life-saving diagnostics and vaccines affordable and easily accessible for people in need. They believe all lives matter, and they are committed to saving as many lives as possible by making their products available to those who can’t afford them.
Cassava Sciences is another company making major waves in the treatment of mental health, in particular, Alzheimer’s disease. While its Sumifilam is still in its clinical trials, it’s outlook is promising. The revolutionary new drug aims to help treat the devastating Alzheimer’s disease by bringing together different proteins to interact properly.
COMPASS Pathways plc (CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is pioneering the development of a new model of psilocybin therapy, in which a proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and the company is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. COMPASS’ meticulous approach to psilocybin treatments is important because, while legalization may look imminent, there’s still a long road ahead for this relatively new medicine.
“There simply isn’t yet enough evidence of safety and efficacy of psilocybin therapy, which is why we’re doing our trials,” adding “the review and approval to regulatory agencies is really the best way ensure the safety, efficacy and quality of any medicine or therapy,” CEO George Goldsmith explained.
Neuronetics, Inc. (STIM) is an industry leader in the development of neuromodulation therapies for neurological disorders and pain management. The company’s products are based on a proprietary delivery platform that uses low-intensity electrical currents to stimulate nerve cells in the brain using electrodes on the surface of the head or via implanted leads directly into targeted areas of the nervous system. Neuronetics has developed both investigational devices and FDA-approved therapeutic devices for use in clinical trials, including deep brain stimulation (DBS) therapy for Parkinson’s disease, essential tremor, dystonia and other movement disorders; peripheral nerve field stimulation (PNFS) therapy for chronic neuropathic pain; vagus nerve stimulator therapy for epilepsy treatment-resistant depression among many others.
Working with its NeuroStar therapy system, the company’s TouchStar protocol is a non-drug, non-invasive transcranial magnetic stimulation (TMS) treatment for Major Depressive Disorder (MDD). Greg Harper, Vice President of Product Development and Operations at Neuronetics, explained, The TouchStar protocol is particularly impactful when paired with our patented Contact Sensing precision technology that provides clinicians with the confidence of knowing they are giving patients the right dose at the exact location.”
Acadia Healthcare Company, Inc. (ACHC) offers a wide range of behavioral health and addiction services to its patients through the use of evidence-based treatment methods. The company is primarily focused on providing a continuum of care for individuals in need with mental health and substance abuse related issues by developing personalized treatment plans that are designed to meet the specific needs of each individual they serve, while also providing support for family members or friends who may be involved in their recovery process.
Acadia Healthcare sets itself apart from other companies in this list due to its approach to the mental health industry. It’s not a drug producer, but rather a treatment provider. Acadia is a multinational behavioral healthcare conglomerate with over 580 facilities across the United States and the United Kingdom. From psychiatric hospitals to residential treatment centers, the company is well-versed in the needs of patients in crisis, providing top-tier services for people suffering from a wide range of mental health issues.
By Charles Kennedy
** IMPORTANT NOTICE AND DISCLAIMER — PLEASE READ CAREFULLY! **
PAID ADVERTISEMENT. This article is a paid advertisement. Advanced Media Solutions Ltd. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Treatment.com International, Inc. Inc. (“Treatment.com” or “Company”) to conduct investor awareness advertising and marketing. Treatment.com paid the Publisher to produce and disseminate six articles profiling the Company at a rate of seventy-five thousand US dollars per article. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Treatment.com) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the company’s products, the anticipated growth of the market for AI-assisted products generally, the anticipated growth of the market for app-based products generally, the anticipated launch date for the company’s products, the anticipated growth of the market for health care app-based products generally, the anticipated launch date for the company’s products, and the anticipated growth and expansion of the medical library to which the company’s products have access. Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the AI technology used in the company’s products, the company’s ability to effectively market the company’s products to customers within its three anticipated revenue streams, supply chain constraints, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY. oilprice.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
DISCLAIMER: OilPrice.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with OilPrice.com or any company mentioned herein. The commentary, views and opinions expressed in this release by OilPrice.com are solely those of OilPrice.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact e-mail: firstname.lastname@example.org U.S. Phone: +1(954)345-0611
The post A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector appeared first on Financial News Media.